CCI Clears ADIA Subsidiary's Acquisition of Berhyanda and MidCo Stakes

The Competition Commission of India (CCI) has given the green light to the proposed acquisition of stakes in Berhyanda Ltd and Berhyanda MidCo Ltd by a subsidiary of the Abu Dhabi Investment Authority (ADIA). This approval was announced on Thursday.

Representative image

Berhyanda and Berhyanda MidCo are wholly-owned funds managed by Advent International, LP. Both entities function as investment holding companies. The CCI's approval includes the acquisition of ordinary shares in these companies by Platinum Poppy C 2024 RSC Ltd, according to a release from the regulator.

Investment Details and Stake Acquisition

Platinum Poppy is a restricted scope company based in the Abu Dhabi Global Market. It was created specifically to invest in Berhyanda and Berhyanda MidCo. ADIA is the ultimate beneficiary of Platinum Poppy, which will secure an indirect non-voting economic interest in Suven Pharmaceuticals Ltd through this investment.

The proposed combination involves acquiring ordinary shares and extending shareholder debt to Berhyanda and Berhyanda MidCo by Platinum Poppy. This move will give Platinum Poppy an indirect stake in Suven Pharmaceuticals, as Berhyanda currently holds a 50.1 per cent stake in Suven.

Suven Pharmaceuticals' Role

Suven Pharmaceuticals Ltd is a publicly listed company engaged in manufacturing and selling active pharmaceutical ingredients and intermediates. It also provides contract development and manufacturing services for intermediates within India.

Deals that exceed certain thresholds require regulatory approval to ensure fair competition and prevent unfair business practices. The CCI monitors such transactions to promote a competitive marketplace.

The CCI's approval is crucial for maintaining market fairness and preventing monopolistic practices. This regulatory oversight ensures that large acquisitions do not stifle competition or harm consumer interests.

This acquisition highlights the ongoing interest of international investors in India's pharmaceutical sector. The involvement of ADIA underscores the attractiveness of Indian pharmaceutical companies to global investors.

The transaction will allow Platinum Poppy to gain economic benefits from Suven Pharmaceuticals without having voting rights. This structure ensures that while they benefit financially, they do not influence the company's strategic decisions directly.

Overall, this deal reflects the dynamic nature of global investments and their impact on Indian industries. The CCI's role remains pivotal in regulating such transactions to maintain a balanced competitive environment.